Wedbush reiterates Outperform rating on Maze Therapeutics, $48 price target

Wedbush reiterated their Outperform rating on Maze Therapeutics's stock with a price target of $48.00.The price target implies an upside of 69.1% from the Sep 22 close of $28.38.Key takeaways from the analyst notePositive Safety Profile: Maze Therapeutics has not reported liver enzyme elevation eve…